Charles Lee and David Barker have been selected to serve on the advisory team of BioNanomatrix.
Lee is director of cytogenetics for the Harvard Cancer Center and an associate professor of pathology at Harvard Medical School.
Barker formerly was chief scientific officer at Illumina, and he was VP and chief science adviser at Amersham Biosciences, and VP of research and business development at Molecular Dynamics.
Kreatech CEO Lex Altink is stepping down from his position with the company and will be replaced by Kees Moonen at an upcoming shareholder meeting.
Altink said in a statement that he is leaving the company because "I consider my mission completed." However, he noted that he will stay on the firm's board as an advisor.
Navigenics has appointed Michael Critelli to its board of directors. Critelli spent nearly three decades at Pitney Bowes, where he was CEO for 11 years and chairman for 12. He currently is chairman of the board for the Dossia Foundation.